证券代码：603883 证券简称：老百姓 公告编号：2023-045 老百姓大药房连锁股份有限公司 2023 年 1-9 月门店增长情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 一、门店增长情况 （二）公司门店覆盖20个省市，通过"自建、并购、加盟、联盟"四驾马车 的网络扩张方式，"聚焦+下沉"拓展"9+7"省优势市场，快速提升目标市场市 占率。同时，运用数智化方式提升精细化管理，通过慢病管理等专业温暖的服务 提升顾客满意度、复购率。 （三）公司加盟业务高速增长，加盟店总数突破4,000家行业领先。第一， 公司加盟店实施类直营的"七统一"高标准管理，商品100%配送，保障加盟店的 发展质量。第二，公司网络广覆盖，给加盟业务发展提供了广阔的发展空间。第 三，公司直营的长期经营，已经在覆盖区域形成了良好的市场口碑、丰富的商品 资源并建立起强大的物流配送体系，具备高效的协同效应。第四，下沉市场成为 公司重点发展方向。长期扎根基层市场的加盟商在当地具备资源优势，能更好地 服务基层市场。 三、风险提示 公司本次披露的 ...

证券代码：603883 证券简称：老百姓 公告编号：2023-044 老百姓大药房连锁股份有限公司 关于召开 2023 年半年度业绩说明会的公告 （一）会议召开时间：2023 年 09 月 22 日 上午 10:00-11:30 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 09 月 22 日(星期五) 上午 10:00-11:30 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 09 月 15 日(星期五) 至 09 月 21 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 ir@lbxdrugs.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 老百姓大药房连锁股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日发布公司 2023 半年度报告，为便于广大投资 ...

证券代码：603883 证券简称：老百姓 老百姓大药房连锁股份有限公司 2023 年半年报解读会纪要 总裁 王黎 财务总监 陈立山 董事会秘书 冯诗倪 证券事务代表 刘遐迩 2.机构参会人员： 中信证券、东北证券、海通证券、中金公司、中信建投证券、摩根士丹利、国 盛证券、兴业证券、华创证券、浙商证券、国金证券、信达证券、东吴证券、 国海证券、东海证券、申万宏源证券、开源证券、招商证券、中银证券、华鑫 证券、华泰证券、野村证券、西部证券、中航证券、西南证券、华西证券、国 泰君安证券、安信证券、东兴证券、平安证券、江海证券、上海证券、汇丰资 管、中信资本、康桥资本、红阳资本、天虫资本、泰康资产、纯达资产、相聚 资本、汇丰晋信、彬元资本、新活力资本、东海资管、华泰证券自营、中信证 券自营、国联证券资管、前海太行资管、成都火星资管、上海明河投资、太平 洋资管、上海庶达资管、尚诚资管、混沌天成资管、源乐晟资管、上汽颀臻资 管、前海精至资管、财通资管、上海慎知资管、上海泊通投资、上海混沌投 资、长江资管、长江养老保险、北京致顺投管、金百镕投管、昭图投管、东盈 投管、泓澄投管、纽富斯投资、光大金控投管、保银投管、前海人寿保 ...

Financial Performance - The company reported a revenue increase of 15% year-over-year for the first half of 2023, reaching approximately CNY 1.5 billion[2]. - The company's operating revenue for the first half of 2023 reached RMB 10,810,860,321, representing a year-on-year increase of 20.24% compared to RMB 8,991,065,651 in the same period last year[19]. - Net profit attributable to shareholders of the listed company was RMB 513,245,443, up 12.43% from RMB 456,500,235 in the previous year[19]. - The company achieved a revenue of 10,810,860.32 million yuan in the first half of 2023, representing a year-on-year growth of 20.24%[53]. - The net profit attributable to shareholders reached 513.25 million yuan, an increase of 12.43% compared to the previous year[53]. - The company's total operating revenue for the first half of 2023 was CNY 2,093,504,241, representing an increase of 12.14% compared to CNY 1,866,932,399 in the same period of 2022[144]. - The net profit for the first half of 2023 was CNY 59,323,292, which is a significant increase of 126.56% from CNY 26,166,319 in the first half of 2022[145]. Market Expansion and Strategy - The company expects a revenue growth guidance of 10-12% for the second half of 2023, driven by new product launches and market expansion[2]. - The company plans to open 50 new stores across various provinces in the next six months to enhance market presence[2]. - The company continues to focus on expanding its Direct-to-Patient (DTP) pharmacy model, enhancing patient services and medication management[16]. - The company aims to become a technology-driven health service platform, expanding into new retail and prescription drug sectors[25]. - The company is actively exploring mergers and acquisitions to enhance its market position and increase the concentration of the retail pharmacy industry[35]. - The company’s strategic focus includes a "9+7" expansion strategy, targeting both core provinces and lower-tier markets[46]. Research and Development - Investment in R&D increased by 25% compared to the previous year, focusing on innovative healthcare solutions[2]. - The company is focusing on digital transformation, enhancing its smart inventory management and marketing capabilities through upgraded digital tools and data governance[48]. Financial Position and Assets - The total assets at the end of the reporting period were RMB 20,991,473,581, a decrease of 1.90% from RMB 21,397,332,918 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 3.55% to RMB 6,761,962,550 from RMB 6,529,953,538 at the end of the previous year[20]. - The company's total liabilities decreased from CNY 14,299,609,510 as of December 31, 2022, to CNY 13,633,811,664 as of June 30, 2023, a decrease of about 4.7%[133]. - The company's total equity increased to CNY 5,639,277,697 from CNY 5,578,514,410, representing a growth of approximately 1.1%[137]. Operational Efficiency - The gross margin improved to 30%, up from 28% in the same period last year, reflecting better cost management[2]. - The company's gross profit margin remained stable, with operating costs increasing by 20.21% to ¥7.27 billion, in line with revenue growth[60]. - The company utilizes advanced logistics systems, including WMS and ERP, to enhance efficiency and reduce errors in its supply chain[30]. Customer and Membership Growth - User data showed a growth in active customers by 20%, totaling 3 million users by the end of June 2023[2]. - The total number of members reached over 79.23 million, with 8.01 million new members added during the reporting period[49]. Environmental and Social Responsibility - The company reported a waste treatment of 0.684 tons of hazardous waste in November 2022 and 0.382 tons in May 2023[86]. - The company donated a total of 22,000 yuan to support rural revitalization projects in the first half of 2023[88]. - The company’s subsidiary, Hunan Yaoshengtang Traditional Chinese Medicine Technology Co., Ltd., passed environmental inspections for its boiler emissions, which were below the required standards[85]. Risks and Challenges - No significant risks were identified that could impact the company's operations during the reporting period[5]. - The company is facing industry policy risks due to stricter regulations in the pharmaceutical retail sector, which may impact short-term performance if not managed properly[75]. - Risks associated with acquisitions include potential underperformance due to market conditions and integration challenges, with measures in place to ensure quality in acquisition targets[76]. Shareholder and Governance - The company has no plans for dividend distribution or capital increase in the near term[3]. - The company has committed to protecting the rights and interests of all shareholders, ensuring equal treatment[93]. - The company has established measures to ensure that any potential dilution of immediate returns from major asset purchases will be compensated[96].

证券代码：603883 证券简称：老百姓 老百姓大药房连锁股份有限公司 机构投资者交流活动会议纪要（2023.7） 一、会议情况 （一）会议时间：2023 年 7 月份 （二）会议形式：现场会议、线上会议 （三）会议地点：公司会议室 （四）参会人员： 1.公司参会人员： 董事会秘书 冯诗倪 证券事务代表 刘遐迩 投资者关系经理 徐磊 投资者关系经理 何林峄 2.机构参会人员： 东北证券、天风证券、国金证券、申万宏源证券、国泰君安证券、兴全基金、天 弘基金、广发基金、国泰基金、财信信托、汇丰银行、丹羿投资、涌津投资等机 构的 24 位投资者。 二、主要内容 投资者提问 问题 1：目前公司所在区域门诊统筹落地进展如何？门诊统筹门店的经营有 什么边际变化？ 回答：公司高度关注各地政策落地情况，门诊统筹向药房放开的政策对于公 司来说中性偏利好，目前 20 个省份中，公司门诊统筹政策已落地 10 个省份。门 诊统筹门店的销售额和店均来客数均优于非门诊统筹门店。后续公司将积极配合 当地政府部门，让门诊统筹向药房放开尽快落地，方便患者便利购药。 问题 2：公司今年的开店计划是否有变化？进展怎样？ 回答：2023 年全年，公 ...

证券代码：603883 证券简称：老百姓 老百姓大药房连锁股份有限公司 机构投资者交流活动会议纪要（2023.6） 一、会议情况 （一）会议时间：2023 年 6 月份 （二）会议形式：现场会议 （三）会议地点：公司会议室 （四）参会人员： 1.公司参会人员： 总裁 王黎 董事会秘书 冯诗倪 证券事务代表 刘遐迩 投资者关系经理 何林峄 2.机构参会人员： 中信建投证券、中信证券、中金公司、东北证券、湘财证券、财信证券、方正证 券、统一证券、凯丰投资、中国银河国际控股有限公司、阿布达比投资局、新加 坡 Arisaig 基金、HW asset management、NSR、Destination Partner、Springs Capital 等机构的 54 位投资者。 二、主要内容 投资者提问 问题 1：公司是否有海外业务扩张的计划？ 回答：公司目前以发展国内市场为主，未来视情况决定是否开展海外业务。 目前公司主要以"聚焦+下沉"为发展策略，其中"9+7"的聚焦战略是在 9 个优 势省份聚焦深耕，通过自建、收购、加盟、联盟共同密集布点；7 省轻资产加盟、 联盟模式为主，利用好现有自营网络大力发展 O2O 线上 ...

重要内容提示： 投资者可于 2023 年 05 月 17 日(星期三) 至 05 月 23 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@lbxdrugs.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 老百姓大药房连锁股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告与 2023 年一季度报告，为便于广大投资者更全面 深入地了解公司 2022 年度及 2023 年一季度经营成果、财务状况，公司计划于 2023 年 05 月 24 日 下午 13:00-14:30 举行 2022 年度暨 2023 年第一季度业绩 说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 会议召开时间：2023 年 05 月 24 日(星期三) 下午 13:00-14:30 会议召开地点： 上海证券 交易所上证路演中心（ 网址： http://roadshow.ssein ...

Financial Performance - The company's revenue for Q1 2023 reached RMB 5,440,515,517, representing a year-on-year increase of 31.39%[4] - Net profit attributable to shareholders was RMB 291,333,643, reflecting a growth of 20.49% compared to the same period last year[4] - The net cash flow from operating activities was RMB 849,191,589, showing a significant increase of 225.53% year-on-year[4] - The basic and diluted earnings per share for the period were both RMB 0.50, an increase of 21.95%[5] - The weighted average return on equity was 4.36%, up by 0.06 percentage points from the previous year[5] - The equity attributable to shareholders increased to RMB 6,747,587,849, marking a growth of 3.33% year-on-year[5] - The net profit attributable to shareholders was RMB 291 million, up 20.49% year-on-year, while the net profit excluding non-recurring items was RMB 281 million, reflecting a 30.20% increase[12] - Total revenue for Q1 2023 reached ¥5,440,515,517, a significant increase of 31.5% compared to ¥4,140,649,849 in Q1 2022[27] - Net profit for Q1 2023 was ¥337,503,746, compared to ¥270,602,719 in Q1 2022, representing a growth of 24.7%[29] - The total comprehensive income for the current period is 333,213,990, up from 268,523,719 in the previous period, indicating a growth of about 24.1%[30] Cash Flow - The net cash flow from operating activities reached RMB 849 million, representing a significant year-on-year growth of 225.53%[12] - Cash inflow from operating activities for the current period is 6,614,001,173, significantly higher than 3,759,516,140 in the previous period, marking an increase of about 76.5%[32] - Cash outflow from operating activities is 5,764,809,584, compared to 3,498,649,816 in the previous period, resulting in a net cash flow from operating activities of 849,191,589, up from 260,866,324, an increase of approximately 225.5%[32] - The net cash flow from investing activities is (201,475,121), an improvement from (446,067,772) in the previous period, indicating a reduction in cash outflow by approximately 55.1%[33] - The net cash flow from financing activities is (595,175,587), compared to 1,115,446,570 in the previous period, showing a decrease in cash outflow of about 153.4%[33] - The ending balance of cash and cash equivalents is 1,448,776,117, compared to 1,609,708,435 in the previous period, reflecting a decrease of approximately 10%[33] Operational Highlights - The company expanded its store network to 11,231 locations, with 7,903 self-operated stores and 3,328 franchised stores, adding 536 new stores in Q1 2023[12] - Membership numbers reached 76.73 million, with an addition of 5.51 million new members in Q1 2023[14] - The company’s supply chain management efficiency improved, with a 68.1% proportion of centralized procurement sales, an increase of 3.5 percentage points year-on-year[13] - The company has established 1,111 outpatient chronic disease designated stores and 162 DTP pharmacies as of Q1 2023[14] - The company’s digital transformation efforts are focused on enhancing operational efficiency and supporting future growth, aiming for a management scale of 50,000 to 100,000 stores[13] - The franchise business saw a revenue increase of nearly RMB 500 million in a single quarter, marking a 45% year-on-year growth[12] - The company achieved a total online sales revenue of 370 million yuan, representing a year-on-year growth of 37%[15] - The self-owned brand sales reached 790 million yuan, with a year-on-year increase of 41%, accounting for 19.5% of total sales, up by 1.7 percentage points from the previous year[15] - The total number of stores reached 11,231, with 7,903 direct-operated stores and 3,328 franchise stores, adding 298 direct-operated stores and 238 franchise stores during the quarter[19] - The retail segment generated revenue of approximately 4.58 billion yuan, with a gross margin of 36.71%, while the revenue growth compared to the previous year was 31.12%[16] - The Central China region generated revenue of approximately 2.36 billion yuan, with a gross margin of 34.96%, showing a revenue growth of 45.22% year-on-year[18] - The company’s O2O delivery service stores reached 8,073, with 500 stores operating 24 hours[15] Assets and Liabilities - Total assets at the end of the reporting period were RMB 21,293,749,220, a slight decrease of 0.48% from the end of the previous year[5] - Current assets decreased to ¥9,150,790,598 from ¥9,463,131,242, a decline of 3.3% year-over-year[25] - Total liabilities decreased to ¥13,961,361,092 from ¥14,299,609,510, a reduction of 2.4%[26] - Shareholder equity increased to ¥7,332,388,128, compared to ¥7,097,723,408, reflecting a growth of 3.3%[26] - The company reported a significant increase in accounts receivable, rising to ¥1,841,410,929 from ¥2,078,069,216, a decrease of 11.4%[25] Research and Development - Research and development expenses were reported at ¥224,510, indicating ongoing investment in innovation[29] Other Financial Metrics - The company reported a decrease in other comprehensive income after tax of (4,289,756), compared to (2,079,000) in the previous period, indicating a decline of approximately 106.4%[30]

Financial Performance - The company reported a total revenue of RMB 10.5 billion for the fiscal year 2022, representing a year-on-year growth of 15%[19]. - The company's operating revenue for 2022 was CNY 20,175,519,303, representing a year-over-year increase of 28.54%[20]. - Net profit attributable to shareholders for 2022 was CNY 784,961,520, up 17.29% from the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 735,724,494, reflecting a growth of 28.52% year-over-year[20]. - The company's revenue exceeded 20 billion yuan, with a total of 10,783 stores, including 7,649 direct-operated and 3,134 franchised stores[29]. - The retail segment generated revenue of CNY 17,597,333,924, with a gross margin of 34.56%, reflecting a decrease of 0.17 percentage points year-on-year[62]. - The company achieved a net profit of 17.88 million yuan for the year 2022, exceeding the forecast of 14.65 million yuan, representing a 21.5% increase[178]. Dividend Distribution - The proposed cash dividend distribution is RMB 5 per 10 shares, totaling RMB 292,403,451, which accounts for 37.25% of the net profit attributable to shareholders for the year[4]. - The company implemented a cash dividend policy, distributing a cash dividend of RMB 0.5 per share, totaling RMB 223,978,654.50, and a capital reserve increase of 0.3 shares per share, resulting in a total share capital of 582,344,502 shares[137]. Share Capital and Structure - The total share capital as of March 31, 2023, is 584,902,902 shares, after deducting 96,000 restricted shares to be repurchased[4]. - The total number of shares increased to 584,902,902 after the issuance of 39,927,820 new shares and a stock dividend distribution[195]. - The company completed a non-public issuance of 39,927,820 shares on February 10, 2022, increasing total shares from 408,673,661 to 448,601,481[198]. - The company granted 2,558,400 restricted shares to 305 incentive recipients as part of its incentive plan[195]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[6]. - The company has outlined various risks and countermeasures in the management discussion section of the report[6]. - The company faces industry policy risks that could impact its operations and market conditions[102]. - The company will closely monitor policy changes and engage industry experts to enhance its understanding and compliance, ensuring proactive adjustments to maintain operational standards[103]. Corporate Governance - The board of directors and management have ensured the authenticity, accuracy, and completeness of the annual report[2]. - The company conducted 4 shareholder meetings during the reporting period, ensuring compliance with legal requirements and maintaining transparency in decision-making[105]. - The board of directors held 13 meetings, with all members fulfilling their duties diligently and adhering to relevant regulations[105]. - The supervisory board convened 10 meetings, actively safeguarding the rights of shareholders and ensuring corporate governance[105]. Market Expansion and Strategy - The company plans to expand its market presence in the northern regions of China, targeting a 20% increase in market share by 2025[19]. - The company is exploring potential acquisitions to enhance its supply chain capabilities and expand its product offerings[19]. - The company aims to capture the prescription drug market by leveraging its high-standard dual-channel stores and DTP stores in response to the trend of prescription outflow[100]. - The company is actively expanding its market presence through a combination of self-operated, franchise, and alliance models, enhancing its competitive edge in the pharmaceutical retail sector[54]. Research and Development - The company has invested RMB 200 million in R&D for innovative pharmacy technologies, aiming to enhance customer service and operational efficiency[19]. - Research and development expenses totaled CNY 111,080,756, accounting for 0.55% of total revenue, with 97.99% of R&D costs capitalized[73]. - The company is investing in technology development, allocating 500 million RMB towards R&D initiatives in the upcoming year[114]. Community Engagement and Social Responsibility - The company invested a total of 3.7866 million yuan in external donations and public welfare projects during the reporting period[152]. - The company donated medical supplies worth CNY 1 million to support pandemic prevention efforts in various regions, including CNY 880,000 worth of supplies to Shaoyang County[153]. - The company supported the construction of cultural squares and road repairs in Dazhuiping Village with a donation of CNY 1 million through the Xixiang Charity Fund[154]. Employee Development and Training - The company achieved a total of 14,969,746 training hours across its workforce, averaging approximately 235 hours of training per employee[133]. - The company developed 819 new courses and launched 1,317 courses on its internal learning platform to enhance employee skills[133]. - The company has established a digital talent training ecosystem to support personalized online learning and precise empowerment[134]. Financial Health and Cash Flow - The company's net cash flow from operating activities was CNY 2,314,315,009, showing a slight increase of 0.70% compared to the previous year[20]. - The net cash flow from investing activities improved significantly, with a decrease in outflow to (¥1,456,649,394) from (¥2,002,151,349), representing a 27.25% reduction[76]. - The total monetary funds at the end of the period reached ¥2,410,922,260, a 71.12% increase from ¥1,408,874,821 in the previous year[78].